Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or the "Company"), a medical technology company with a pioneering navigated non-invasive brain stimulation system, announces that, pursuant to the authorisations received from the Company's Extraordinary General Meeting on 18 August 2016 and the financing arrangement entered into with Bracknor Investment which was announced on 21 July, the Board of Directors of the Company has today resolved to approve Bracknor's request to convert EUR 350,000 of the convertible bond to Company's shares at issue price of EUR 0,10727. The Board of Director’s has resolved to transfer a total of 3,262,794 new shares of the Company to Bracknor. The board of directors of the Company has also resolved to issue 5,372,641 new treasury shares to the Company itself without payment and to list the new shares issued pursuant to the above resolutions. The new shares will be listed approximately on 13thJanuary 2017. After the issuance the Company will have 5,572,318 treasury shares and the total number of shares in the Company is 55,723,184.
Martin Jamieson, CEO
Martin Jamieson, Chairman and CEO
UB Securities Oy (Certified Adviser)
+358 (0)9 2538 0246
About Nexstim Plc
Nexstim is a medical technology company which has pioneered its technology in brain diagnostics with the Navigated Brain Stimulation (NBS) system. It is the first and only FDA cleared and CE marked system based on navigated Transcranial Magnetic Stimulation (nTMS) for pre-surgical mapping of the speech and motor cortices of the brain. Based on the same technology platform, the Company has developed a system called Navigated Brain Therapy (NBT®) which is CE marked for the treatment of chronic neuropathic pain, major depression and stroke. Nexstim shares are listed on the Nasdaq First North Finland and Nasdaq First North Sweden-. For more information please visit www.nexstim.com.